Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Several companies could vie for next-gen COVID-19 vaccine market share

By Brian Buntz | July 8, 2021

COVID-19 therapies vaccines coronavirus

[Photo by Daniel Schludi on Unsplash]

A couple of years ago, mRNA vaccines remained at the research stage. Now, they are among the best-selling pharmaceutical products with Pfizer (NYSE:PFE), BioNTech (NSDQ:BNTX) and Moderna (NSDQ:MRNA) dominating the market.

However, that could change in the long run as a growing number of companies develop next-generation mRNA COVID-19 vaccines, which promise to be more effective and less likely to cause side effects than their predecessors.

While mRNA COVID-19 vaccines are among the most effective vaccines against the novel coronavirus, researchers have linked their use to rare side effects such as myocarditis.

Future mRNA may be better tolerated. mRNA itself promotes an immune response future mRNA vaccines could optimize reactogenicity through refining the dose or structure of the single-stranded RNA molecule. 

Such next-gen vaccines will also likely be more effective against SARS-CoV-2 variants. While the mRNA vaccines from Pfizer/BioNTech and Moderna were approximately 95% efficacious against early lineages of SARS-CoV-2, they appear to be less effective against the Delta variant and other variants of concern. 

Contenders looking to compete in the next-gen COVID-19 mRNA-based vaccine market include a mix of Western and Asian players.  

CureVac (NSDQ:CVAC): CVnCoV, CureVac’s first vaccine offering, disappointed with 48% efficacy in a pivotal trial. But the company is partnering with GSK to develop monovalent and multivalent vaccine candidates based on an mRNA platform that could offer substantially better protection. Early data show that the CV2CoV vaccine led to a ten-fold increase in neutralizing antibody levels compared with CVnCoV. 

Moderna: The mRNA-focused company is developing mRNA-1273.351, a vaccine optimized for the Beta variant that first emerged in South Africa. It is also testing a vaccine known as mRNA-1273.211, a 50/50 mix of its first-gen vaccine and mRNA-1273.351 vaccine. 

Pfizer: While Pfizer and its partner BioNTech have confirmed they are testing the use of their BNT162b2 vaccine as a booster, the companies have not yet shared details on their plans for future mRNA-based COVID-19 vaccines. In February, however, Pfizer confirmed it was working with BioNTech to “evaluate a variant-specific vaccine having a modified mRNA sequence.” At that time, the company said it was developing a vaccine based on the B.1.351 (Beta) lineage. More recently, it has acknowledged that it is also working on a vaccine targeting the Delta variant of SARS-CoV-2. 

Sanofi (EPA:SAN): One of the top vaccine producers overall, Sanofi is a relatively late-comer to mRNA-based vaccines. But the company recently announced that it was investing $477 million annually in developing mRNA vaccines. Sanofi, however, hasn’t confirmed which diseases it will target with mRNA vaccines. It’s hinted that it would develop an mRNA flu vaccine candidate. Sanofi has also committed to assisting Moderna with the production of its vaccine. Separately, it is working with GSK on a non-mRNA–based COVID-19 vaccine.  

Suzhou Ribo: The China-based company has patents for its mRNA-based COVID-19 based vaccine that can potentially be stored at refrigerator temperatures. 

StemiRNA: StemiRNA has licensed an mRNA platform from a U.S. firm. The company is exploring the use of a lipopolyplex (LPP) nano-delivery platform. In contrast to the lipid nanoparticle platforms from first-generation mRNA-based COVID-19 vaccines, the LPP platform offers slower expression. While lipid nanoparticle formulations express mRNA in approximately 12 hours, LPP vaccine expression can occur in a window of seven to 14 days. Lipopolyplexes, however, may have greater toxicity than lipid nanoparticles. 

WalVax (SHE:300142): The company is also working on an mRNA COVID-19 vaccine candidate in collaboration with Abogen and the PLA Academy of Military Science. A Phase 3 clinical trial for the vaccine are underway. Some 6,000 volunteers in Mexico are taking part in the study.  

CanSino Biologics (HKG:6185): The company is partnering with Precision NanoSystems to develop its mRNA vaccine. Precision Nano Systems is a microfluidic device specialist with experience producing lipid nanoparticles. In their collaboration, Precision NanoSystems is focusing on vaccine design, while CanSino plans to focus on everything from preclinical and clinical development to commercialization. 

AIM Vaccine Co: AIM Vaccine Co. acquired Liverna in May. Liverna had been collaborating with Amicus Therapeutics to develop an mRNA vaccine.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AIM Vaccine Co., BioNTech, CanSino Biologics, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, CureVac, Pfizer, Sanofi, StemiRNA, Suzhou Ribo, WalVax
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE